Corcept officer proposes $1.15M share sale

Earlier reported sales include 10,000 shares on September 14, 2026, and 1,540 shares on August 3, 2026.

Rhea-AI Filing Summary

Corcept Therapeutics (CORT) officer Joseph D. Lyon reported a proposed sale of 10,000 common shares, with an aggregate market value of $1,152,300.00, on October 1, 2026, through Stifel Nicolaus. The shares are listed as acquired from the issuer through a stock option exercise for cash. Earlier reported sales were 1,540 shares for $175,725.77 on August 3, 2026, and 10,000 shares for $1,134,423.74 on September 14, 2026.

Key Figures

Proposed sale: 10,000 shares Aggregate market value: $1,152,300.00 Shares outstanding: 108,100,000 shares +4 more

7 metrics

Proposed sale 10,000 shares October 1, 2026

Aggregate market value $1,152,300.00 Proposed sale

Shares outstanding 108,100,000 shares Securities information

Prior sale 1,540 shares August 3, 2026

Prior sale proceeds $175,725.77 August 3, 2026

Prior sale 10,000 shares September 14, 2026

Prior sale proceeds $1,134,423.74 September 14, 2026

Key Terms

Rule 144, stock option exercise

2 terms

Rule 144 regulatory

"definition of "person" in paragraph (a) of Rule 144"

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

stock option exercise financial

"stock option exercise"

A stock option exercise is the act of using a previously granted right to buy shares of a company's stock at a specific, predetermined price by paying that price and receiving the shares. It matters to investors because exercising changes who owns the shares (which can dilute existing ownership), can trigger taxable events and shift potential gains or losses, and affects voting power and the company’s outstanding share count—like turning a voucher into an actual product that becomes part of circulating supply.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many CORT shares does Joseph D. Lyon plan to sell?

Joseph D. Lyon’s notice lists a proposed sale of 10,000 common shares on October 1, 2026, with an aggregate market value of $1,152,300.00. Stifel Nicolaus is named as the broker for the proposed sale.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 10/01/2026 - 11:09 AM Accepted by SEC EDGAR 10/01/2026 - 11:09 AM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001817838
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	CORCEPT THERAPEUTICS INC
SEC File Number	000-50679
Address of Issuer	101 REDWOOD SHORES PARKWAY REDWOOD CITY CALIFORNIA 94065
Phone	650.688.8803
Name of Person for Whose Account the Securities are To Be Sold	Lyon Joseph Douglas
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
common	Stifel Nicolaus 501 N Broadway St Louis MO 63102	10000	1152300.00	108100000	10/01/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
common	10/01/2026	stock option exercise	Issuer			10000	10/01/2026	cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Joseph D Lyon 101 Redwood Shores Parkway Redwood City CA 94065	common	08/03/2026	1540	175725.77
Joseph D Lyon 101 Redwood Shores Parkway Redwood City CA 94065	common	09/14/2026	10000	1134423.74

144: Remarks and Signature

Remarks
Date of Notice	10/01/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	06/10/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	Joseph D Lyon
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)